Ovavax2 Accelerating scale up and commercialisation of 100% bacteria free eggs for use in production of vaccines
- Coordinator
- Ovagen Group Limited, Ireland
- Runs
- 1 November 2022 to 31 October 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190136873
What the project is doing
In the project's own words, from its summary on CORDIS.
Ovagen is aiming to transform the egg-based production of vaccines and other biopharmaceutical medicines by producing the world’s first Germ Free egg and bringing it into mass production. The proposed programme of work will build on the groundwork initiated as part of the 30 month OvaVax project (GA 858390) and provides a logical expansion of this disruptive, innovative technology to the challenges facing the world as it comes to grips with COVID-19 and future pandemics with the need for rapid scale-up of vaccine production Ovagen is applying for EIC Accelerator funding to broaden the project scope of their existing H2020 SME Instrument Phase 2 to expand and accelerate the existing influenza project, to include COVID-19, Yellow Fever, Newcastle Disease and to include readiness for production and accelerated international scaleup of germ free egg production to increase global vaccine manufacturing capacity in readiness for future pandemics similar to COVID-19.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ovagen Group Limited | Ballina | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI